Janus Henderson Group PLC increased its holdings in Edwards Lifesciences Corp (NYSE:EW) by 117.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,505,128 shares of the medical research company’s stock after buying an additional 1,350,879 shares during the period. Janus Henderson Group PLC’s holdings in Edwards Lifesciences were worth $436,144,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of the stock. FMR LLC grew its holdings in shares of Edwards Lifesciences by 32.9% during the second quarter. FMR LLC now owns 6,714,684 shares of the medical research company’s stock valued at $977,456,000 after buying an additional 1,663,511 shares during the last quarter. Brown Advisory Inc. grew its holdings in shares of Edwards Lifesciences by 5.8% during the second quarter. Brown Advisory Inc. now owns 3,866,016 shares of the medical research company’s stock valued at $562,775,000 after buying an additional 211,258 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Edwards Lifesciences by 5.3% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,147,510 shares of the medical research company’s stock valued at $312,614,000 after buying an additional 107,676 shares during the last quarter. Jennison Associates LLC grew its holdings in shares of Edwards Lifesciences by 70.8% during the third quarter. Jennison Associates LLC now owns 1,444,384 shares of the medical research company’s stock valued at $251,467,000 after buying an additional 598,735 shares during the last quarter. Finally, Morgan Stanley grew its holdings in shares of Edwards Lifesciences by 38.4% during the second quarter. Morgan Stanley now owns 1,329,458 shares of the medical research company’s stock valued at $193,531,000 after buying an additional 369,027 shares during the last quarter. 81.27% of the stock is owned by institutional investors.

A number of equities research analysts have recently weighed in on EW shares. Zacks Investment Research raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a report on Wednesday, September 26th. Bank of America lowered shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating in a report on Tuesday, October 2nd. Guggenheim lowered shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating in a report on Tuesday, October 2nd. Northland Securities reissued a “hold” rating and set a $120.00 price objective on shares of Edwards Lifesciences in a report on Thursday, October 11th. Finally, SunTrust Banks boosted their price objective on shares of Edwards Lifesciences to $200.00 and gave the company a “buy” rating in a report on Friday, September 28th. Two analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $156.79.

In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 32,900 shares of the company’s stock in a transaction dated Monday, October 29th. The shares were sold at an average price of $140.74, for a total value of $4,630,346.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Scott B. Ullem sold 25,036 shares of the company’s stock in a transaction dated Wednesday, September 5th. The stock was sold at an average price of $140.04, for a total transaction of $3,506,041.44. Following the completion of the transaction, the chief financial officer now owns 41,019 shares of the company’s stock, valued at approximately $5,744,300.76. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 156,611 shares of company stock worth $22,651,084. 1.84% of the stock is owned by corporate insiders.

NYSE:EW opened at $149.88 on Tuesday. Edwards Lifesciences Corp has a one year low of $106.53 and a one year high of $175.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.85 and a current ratio of 2.31. The firm has a market capitalization of $32.55 billion, a price-to-earnings ratio of 39.44, a price-to-earnings-growth ratio of 2.05 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, October 23rd. The medical research company reported $1.07 EPS for the quarter, beating the consensus estimate of $1.02 by $0.05. Edwards Lifesciences had a net margin of 20.67% and a return on equity of 30.11%. The company had revenue of $906.60 million for the quarter, compared to analyst estimates of $927.56 million. During the same period in the prior year, the company earned $0.84 earnings per share. The firm’s revenue was up 10.4% on a year-over-year basis. Sell-side analysts anticipate that Edwards Lifesciences Corp will post 4.7 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This news story was posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dailypolitical.com/2018/11/20/janus-henderson-group-plc-acquires-1350879-shares-of-edwards-lifesciences-corp-ew.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Featured Story: What is systematic risk?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.